Siwers B, Borg S, d'Elia G, Lundin G, Forshell G P, Raotma H, Román G
Acta Psychiatr Scand. 1977 Jan;55(1):21-31. doi: 10.1111/j.1600-0447.1977.tb00137.x.
A multicentre comparative clinical evaluation of lofepramine, an imipramine analogue, and imipramine has been made with double-blind technique and fixed dosage (lofepramine 70 mg t.i.d., imipramine 50 mg t.i.d.). Plasma was drawn after 3 weeks for determination of noradrenaline-uptake inhibitory capacity of the parent compound and/or its active metabolites. Plasma concentrations of lofepramine and desmethylimipramine (DMI) were determined in the same samples. The concentrations of lofepramine in the whole material were low (5-27 ng/ml) except for one patient who had a level of 53 ng/ml. In both groups of patients there was an almost 40-fold range in the plasma levels of DMI or apparent DMI. The patients were rated for severity of depression before treatment, then once weekly for 3 weeks and finally during the fifth week. For further information concerning the psychiatric aspects, see d'Elia et al. in this issue (1977). A significant correlation was found between the concentrations of DMI and the noradrenaline-uptake inhibitory capacity in the plasma samples. No correlations were found between uptake inhibitory capacity of plasma samples and the amelioration scores.
采用双盲技术和固定剂量（洛非帕明70毫克每日三次，丙咪嗪50毫克每日三次）对丙咪嗪类似物洛非帕明和丙咪嗪进行了多中心比较临床评估。3周后采集血浆，以测定母体化合物和/或其活性代谢物的去甲肾上腺素摄取抑制能力。在相同样本中测定洛非帕明和去甲丙咪嗪（DMI）的血浆浓度。除一名患者的水平为53纳克/毫升外，整个样本中洛非帕明的浓度较低（5 - 27纳克/毫升）。两组患者中，DMI或表观DMI的血浆水平范围几乎相差40倍。在治疗前对患者的抑郁严重程度进行评分，然后每周一次，持续3周，最后在第5周进行评分。有关精神方面的更多信息，请参阅本期d'Elia等人的文章（1977年）。在血浆样本中，发现DMI浓度与去甲肾上腺素摄取抑制能力之间存在显著相关性。未发现血浆样本的摄取抑制能力与改善评分之间存在相关性。
